DK1392348T3 - Behandling af demens og neurodegenerative sygdomme med moderate doser af LHRH antagonister - Google Patents

Behandling af demens og neurodegenerative sygdomme med moderate doser af LHRH antagonister

Info

Publication number
DK1392348T3
DK1392348T3 DK02735312T DK02735312T DK1392348T3 DK 1392348 T3 DK1392348 T3 DK 1392348T3 DK 02735312 T DK02735312 T DK 02735312T DK 02735312 T DK02735312 T DK 02735312T DK 1392348 T3 DK1392348 T3 DK 1392348T3
Authority
DK
Denmark
Prior art keywords
dementia
treatment
neurodegenerative diseases
lhrh antagonists
moderate doses
Prior art date
Application number
DK02735312T
Other languages
Danish (da)
English (en)
Inventor
Rainer Voegeli
Juergen Engel
Original Assignee
Aeterna Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeterna Zentaris Gmbh filed Critical Aeterna Zentaris Gmbh
Application granted granted Critical
Publication of DK1392348T3 publication Critical patent/DK1392348T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DK02735312T 2001-04-30 2002-04-27 Behandling af demens og neurodegenerative sygdomme med moderate doser af LHRH antagonister DK1392348T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28743401P 2001-04-30 2001-04-30
PCT/EP2002/004677 WO2002102401A1 (en) 2001-04-30 2002-04-27 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists

Publications (1)

Publication Number Publication Date
DK1392348T3 true DK1392348T3 (da) 2008-09-29

Family

ID=23102886

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02735312T DK1392348T3 (da) 2001-04-30 2002-04-27 Behandling af demens og neurodegenerative sygdomme med moderate doser af LHRH antagonister

Country Status (27)

Country Link
US (1) US7288517B2 (https=)
EP (1) EP1392348B1 (https=)
JP (1) JP2004529207A (https=)
KR (1) KR20040000446A (https=)
CN (1) CN1317030C (https=)
AT (1) ATE400287T1 (https=)
AU (1) AU2002310788B2 (https=)
BG (1) BG108339A (https=)
BR (1) BR0209290A (https=)
CA (1) CA2444876A1 (https=)
CZ (1) CZ20033167A3 (https=)
DE (1) DE60227507D1 (https=)
DK (1) DK1392348T3 (https=)
ES (1) ES2307760T3 (https=)
HU (1) HUP0400067A2 (https=)
IL (1) IL156777A0 (https=)
MX (1) MXPA03008666A (https=)
NO (1) NO20034322L (https=)
NZ (1) NZ544417A (https=)
PL (1) PL362319A1 (https=)
PT (1) PT1392348E (https=)
RU (1) RU2319501C2 (https=)
SI (1) SI1392348T1 (https=)
SK (1) SK14512003A3 (https=)
UA (1) UA80679C2 (https=)
WO (1) WO2002102401A1 (https=)
ZA (1) ZA200305326B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US20020077327A1 (en) * 1999-09-23 2002-06-20 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US6960591B2 (en) * 2000-07-05 2005-11-01 Yamanouchi Pharmaceutical Co., Ltd. Propane-1,3-dione derivative
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
US7709519B2 (en) * 2004-06-04 2010-05-04 Astellas Pharma Inc. Benzimidazolylidene propane-1,3 dione derivative or salt thereof
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
US20060142186A1 (en) * 2004-12-23 2006-06-29 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of alzheimer's disease
EP1864976B1 (en) 2005-03-31 2012-10-10 Astellas Pharma Inc. Propane-1,3-dion derivative or salt thereof
CN101573352A (zh) * 2006-10-21 2009-11-04 艾博特股份有限两合公司 杂环化合物和其作为糖原合酶激酶3抑制剂的用途
KR20100056508A (ko) * 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 폐렴 연쇄상 구균 감염의 치료를 위한 bfgf 1-24 및 임의의 (arg 8)바소프레신의 용도
WO2009033730A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratoires Ag Peptide gxgrgdspca as a therapeutic agent
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
EP2307040B1 (en) * 2008-05-29 2015-09-09 Isr Immune System Regulation Ab Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids
MX336726B (es) 2010-09-27 2016-01-27 Abbott Gmbh & Co Kg Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases
WO2025155903A1 (en) * 2024-01-19 2025-07-24 Temple University-Of The Commonwealth System Of Higher Education Compositions of antioxidant translation modulators for treating neurodegenerative disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
AU710926B2 (en) 1996-05-20 1999-09-30 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
CA2372044A1 (en) 1999-05-14 2000-11-23 Neurocrine Biosciences, Inc. Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
CA2309395A1 (en) * 1999-06-04 2000-12-04 Richard Lloyd Bowen Methods for preventing and treating alzheimer's disease
MXPA02003614A (es) * 1999-10-15 2002-10-23 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de ganadotropina y metodos relacionados con los mismos..
US20030134863A1 (en) 2000-04-13 2003-07-17 Shuichi Furuya Preventives/remedies for alzheimer's disease
US6960591B2 (en) * 2000-07-05 2005-11-01 Yamanouchi Pharmaceutical Co., Ltd. Propane-1,3-dione derivative

Also Published As

Publication number Publication date
NO20034322D0 (no) 2003-09-26
US20020177556A1 (en) 2002-11-28
UA80679C2 (en) 2007-10-25
MXPA03008666A (es) 2004-10-15
CN1575185A (zh) 2005-02-02
HK1072000A1 (en) 2005-08-12
SK14512003A3 (sk) 2004-08-03
ES2307760T3 (es) 2008-12-01
BG108339A (bg) 2004-11-30
BR0209290A (pt) 2004-07-13
EP1392348A1 (en) 2004-03-03
HUP0400067A2 (hu) 2004-04-28
CZ20033167A3 (cs) 2004-08-18
JP2004529207A (ja) 2004-09-24
IL156777A0 (en) 2004-02-08
PT1392348E (pt) 2008-09-09
ATE400287T1 (de) 2008-07-15
CN1317030C (zh) 2007-05-23
NZ544417A (en) 2008-03-28
WO2002102401A1 (en) 2002-12-27
DE60227507D1 (de) 2008-08-21
CA2444876A1 (en) 2002-12-27
PL362319A1 (en) 2004-10-18
RU2319501C2 (ru) 2008-03-20
EP1392348B1 (en) 2008-07-09
ZA200305326B (en) 2003-07-30
NO20034322L (no) 2003-09-26
AU2002310788B2 (en) 2007-04-05
KR20040000446A (ko) 2004-01-03
RU2003134949A (ru) 2005-02-10
SI1392348T1 (sl) 2008-12-31
US7288517B2 (en) 2007-10-30

Similar Documents

Publication Publication Date Title
DK1392348T3 (da) Behandling af demens og neurodegenerative sygdomme med moderate doser af LHRH antagonister
EE200200716A (et) Ühendid Alzheimeri tõve käitluseks
LU92854I2 (fr) Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil
NO20022531D0 (no) Vaksine for forebyggelse og behandling av Alzheimer og amyloidrelaterte sykdommer
EP1613347A4 (en) BETA AMYLOID PEPTIDE DETECTING HUMANIZED ANTIBODIES
EA200401473A1 (ru) Предотвращение и лечение амилоидогенного заболевания
EA200602015A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
DE69533174D1 (de) Pyridopyrimidinone, chinoline und anellierte n-heterozyklen als bradykinin-antagonisten
ATE314343T1 (de) Verbindungen zur behandlung der alzheimerischen krankheit
EA200400352A1 (ru) Органолептически приемлемые распадающиеся во рту композиции
EA200301223A1 (ru) Лекарственные формы окскарбазепина
ATE506959T1 (de) Verwendung von il-18 inhibitoren
PA8556701A1 (es) Derivados del 3-azabiciclo(3.1.0)hexano
NO20042208L (no) Vaginalt administrerte anti-dysrytmiske midler for behandling av bekkensmerter
EA200201138A1 (ru) Пептид, модулирующий рецептор тромбопоэтина
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
DE60014343D1 (de) N-(2-phenyl-4-amino-butyl)-1-naphthamide als neurokinin-1 rezeptorantagonisten
DK1007040T3 (da) Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom
EP1448193A4 (en) THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEAMIC CONDITIONS
TR200103638T2 (tr) IL-8 Reseptör antagonistleri
DE60028928D1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
ATE374203T1 (de) Therapeutische verbindungen und verfahren
EP1458694A4 (en) THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEAMIC CONDITIONS
DE60137451D1 (de) N-substituierte Amide als NK1 Rezeptor Antagonisten
MXPA03008406A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos y agentes antagonistas de endotelina.